Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 226 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Seizure Disorder, Partial Clear all
Completed Phase 1 Interventional

High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy

NCT02264652
View directory record Official record
Conditions
Epilepsy
Interventions
HD Transcranial Direct Stimulation
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
9 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Jul 21, 2026, 6:07 PM EDT
Terminated Not applicable Interventional Results available

Maintenance TMS in Treatment Resistant Depression

NCT06682299
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Transmagnetic Stimulation, Electroconvulsive Therapy
Device
Lead sponsor
Austin Messner
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy

NCT00228969
View directory record Official record
Conditions
Refractory Epilepsy
Interventions
RWJ-333369
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
29
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional

Evaluation Phenobarbital as Adjunctive Therapy in Participants With Partial Onset Seizures

NCT01284556
View directory record Official record
Conditions
Epilepsy
Interventions
Phenobarbital, Placebo tablet
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
17 Years to 70 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 21, 2026, 6:07 PM EDT
Terminated Phase 3 Interventional

Clobazam Use in Epilepsia Partialis Continua - Pilot Study

NCT02134366
View directory record Official record
Conditions
Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
Interventions
Clobazam, Clonazepam, Lorazepam
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Tolerability of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial Seizures

NCT00151879
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
SPM 927
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
RTP, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 21, 2026, 6:07 PM EDT
Terminated Phase 4 Interventional Results available

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

NCT02090998
View directory record Official record
Conditions
Transformed Migraine, Chronic Daily Headache
Interventions
SPG Block with 5% Lidocaine gel, Amitriptyline
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy

NCT01728077
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB Pharma SA
Industry
Eligibility
16 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Little Rock, Arkansas • Lexington, Kentucky • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Jul 21, 2026, 6:07 PM EDT
Enrolling by invitation Not applicable Interventional

Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy

NCT02151175
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
LIFUP
Device
Lead sponsor
BrainSonix Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 2 Interventional Results available

Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures

NCT00871377
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, High Dose Fish Oil, Low Dose Fish Oil
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Imaging the Effect of Centrotemporal Spikes and Seizures on Language in Children

NCT01521130
View directory record Official record
Conditions
Benign Childhood Epilepsy With Centro-Temporal Spikes
Interventions
Levetiracetam
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 13 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Jul 21, 2026, 6:07 PM EDT
Completed No phase listed Observational

Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism

NCT00001489
View directory record Official record
Conditions
Epilepsy, Epilepsy, Complex Partial
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 21, 2026, 6:07 PM EDT
Withdrawn Phase 2 Interventional

Safety and Anticonvulsant Efficacy of Passiflora Incarnata Extract in Patients With Partial Epilepsy

NCT00982787
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Botanical extract from Passiflora incarnata
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy

NCT00235755
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
77
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Investigate the Efficacy and Safety of Lacosamide as an Add on Therapy in Children With Epilepsy With Partial-onset Seizures

NCT01964560
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Month to 17 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy

NCT00986310
View directory record Official record
Conditions
Uncontrolled Partial Epilepsy, Ictal Hypoventilation
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional Results available

An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

NCT04686786
View directory record Official record
Conditions
Seizures
Interventions
CVL-865
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
26
States / cities
Little Rock, Arkansas • New Haven, Connecticut • Gulf Breeze, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Not applicable Interventional

The Effect of Music Periodicity on Interictal Epileptiform Discharges

NCT01515436
View directory record Official record
Conditions
Rolandic Epilepsy, Benign Childhood Epilepsy With Centrotemporal Spikes, Epilepsy, Seizures
Interventions
Mozart alternating with Beethoven, Beethoven alternating with Mozart
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Jul 21, 2026, 6:07 PM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy

NCT01501383
View directory record Official record
Conditions
Epilepsy
Interventions
VX-765 Part A, Placebo, VX-765 Part B
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
22
States / cities
Northport, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Jul 21, 2026, 6:07 PM EDT
Completed No phase listed Observational

The Human Epilepsy Project

NCT02126774
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 60 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
26
States / cities
Birmingham, Alabama • San Francisco, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 21, 2026, 6:07 PM EDT
Not listed No phase listed Observational

Brain Development Research Program

NCT00305305
View directory record Official record
Conditions
Brain Disorders, Aicardi Syndrome
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 21, 2026, 6:07 PM EDT
Not yet recruiting Not applicable Interventional

Overnight TI in TLE

NCT07434986
View directory record Official record
Conditions
Temporal Lobe Epilepsy (TLE), Drug Resistant Epilepsy, Sleep
Interventions
Non-invasive Temporal Interference (TI) Stimulation Targeting Bilateral Hippocampi
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 21, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Eslicarbazepine Acetate Monotherapy Long Term Study

NCT00910247
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
96
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Jul 21, 2026, 6:07 PM EDT